Concerning lymphoid blast phase CML with TKI-resistant T315I mutations, it was first demonstrated in a 56-year-old man that anti-CD19 CAR-T-cell therapy eliminates CD19+ blasts [13]. Here, CD19 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.